Trailing TRAIL Resistance: Novel Targets for TRAIL Sensitization in Cancer Cells
about
FAK and paxillin, two potential targets in pancreatic cancerGinsenoside compound K sensitizes human colon cancer cells to TRAIL-induced apoptosis via autophagy-dependent and -independent DR5 upregulationLeveraging Cancer Therapeutics for the HIV Cure Agenda: Current Status and Future DirectionsA promising "TRAIL" of tanshinones for cancer therapy.Synergistic effects of combined treatment with histone deacetylase inhibitor suberoylanilide hydroxamic acid and TRAIL on human breast cancer cells.Therapeutic applications of TRAIL receptor agonists in cancer and beyond.Discovery and characterization of Isofistularin-3, a marine brominated alkaloid, as a new DNA demethylating agent inducing cell cycle arrest and sensitization to TRAIL in cancer cells.MiR-424 and miR-27a increase TRAIL sensitivity of acute myeloid leukemia by targeting PLAG1Death receptor 5 (DR5) and a 5-gene apoptotic biomarker panel with significant differential diagnostic potential in colorectal cancer.DR5 mAb-conjugated, DTIC-loaded immuno-nanoparticles effectively and specifically kill malignant melanoma cells in vivo.Quinacrine induces apoptosis in cancer cells by forming a functional bridge between TRAIL-DR5 complex and modulating the mitochondrial intrinsic cascade.Gold nanoparticles enhance TRAIL sensitivity through Drp1-mediated apoptotic and autophagic mitochondrial fission in NSCLC cellsBufalin sensitizes human bladder carcinoma cells to TRAIL-mediated apoptosis.ML327 induces apoptosis and sensitizes Ewing sarcoma cells to TNF-related apoptosis-inducing ligand.Chemoresistance is associated with overexpression of HAX-1, inhibition of which resensitizes drug-resistant breast cancer cells to chemotherapy.Valosin-containing Protein is a Target of 5'-l Fuligocandin B and Enhances TRAIL Resistance in Cancer Cells.MiR-106b inhibitors sensitize TRAIL-induced apoptosis in hepatocellular carcinoma through increase of death receptor 4.Mechanisms of tumor cell resistance to the current targeted-therapy agents.Effect of vitamin E succinate on the expression of the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor in gastric cancer cells and CD4(+) T cells.Intracellular localization of DR5 and related regulatory pathways as a mechanism of resistance to TRAIL in cancer.Knockdown of miR-27a sensitizes colorectal cancer stem cells to TRAIL by promoting the formation of Apaf-1-caspase-9 complex.Combination of AAV-TRAIL with miR-221-Zip Therapeutic Strategy Overcomes the Resistance to TRAIL Induced Apoptosis in Liver Cancer.NGF sensitizes TrkA SH-SY5Y neuroblastoma cells to TRAIL-induced apoptosis.TRAIL induces pro-apoptotic crosstalk between the TRAIL-receptor signaling pathway and TrkAIII in SH-SY5Y cells, unveiling a potential therapeutic "Achilles heel" for the TrkAIII oncoprotein in neuroblastoma.Protective Role for TWEAK/Fn14 in Regulating Acute Intestinal Inflammation and Colitis-Associated Tumorigenesis.Sharkquinone, a new ana-quinonoid tetracene derivative from marine-derived Streptomyces sp. EGY1 with TRAIL resistance-overcoming activity.cFLIP critically modulates apoptotic resistance in epithelial-to-mesenchymal transition.Cell death and restoration of TRAIL-sensitivity by ciglitazone in resistant cervical cancer cells.Hsp90 inhibitor sensitizes TRAIL-mediated apoptosis via chop-dependent DR5 upregulation in colon cancer cells.Nanocarriers for TRAIL delivery: driving TRAIL back on track for cancer therapy.Trichosanthin enhances sensitivity of non-small cell lung cancer (NSCLC) TRAIL-resistance cells.RGD and NGR modified TRAIL protein exhibited potent anti-metastasis effects on TRAIL-insensitive cancer cells in vitro and in vivo.A Genome-Wide Loss-of-Function Screen Identifies SLC26A2 as a Novel Mediator of TRAIL Resistance.The novel TRAIL-receptor agonist APG350 exerts superior therapeutic activity in pancreatic cancer cells.Lambertianic Acid Sensitizes Non-Small Cell Lung Cancers to TRAIL-Induced Apoptosis via Inhibition of XIAP/NF-κB and Activation of Caspases and Death Receptor 4.The regulation of combined treatment-induced cell death with recombinant TRAIL and bortezomib through TRAIL signaling in TRAIL-resistant cells.Relationship between the agonist activity of synthetic ligands of TRAIL-R2 and their cell surface binding modes.HDAC4 degradation by combined TRAIL and valproic acid treatment induces apoptotic cell death of TRAIL-resistant head and neck cancer cells
P2860
Q26765360-EFACF110-B254-4782-9756-988ED07108CCQ28394059-D64C8F7B-1526-4BC4-8B48-05556233770AQ36030989-E2AFFF3A-F138-4C09-BC5C-4014B4744E25Q36332681-1ED16213-506A-418E-A693-A817AAE4477BQ36996317-605F979D-ED55-49D8-B307-F9BAC2903838Q37114025-C9912E81-55FD-4D1E-9231-0EF6C23A7534Q37269205-FAA21182-8CAD-4190-87F6-A305FDF91453Q37295313-D12AD6B0-7C4C-43B0-86FD-4FC0B3099200Q37402581-703528D8-F15A-4F27-ACF0-A09E7223C360Q37636774-593D7DB6-56BF-4D37-BC9E-1CF61FA3E11CQ37702210-64E5F9C9-A70C-4024-8939-02A37BAA1323Q37739975-B6AC1736-BDE7-4BB2-983B-EE0761A6D3CBQ38686012-BE319965-BF6D-4A52-B706-CA1A43F6175BQ38697040-1BB9F657-A108-44D7-83B2-CB9FCCCCA6EEQ38710235-5CCD91B9-1194-4DE1-A6A8-D5E1F67BC900Q38723897-19649B31-E2AE-4360-822B-5C4A18043963Q38730350-F6E3C0F1-FB85-4E93-A16C-5008B7DF3312Q38828353-C9300D74-CFF0-4D49-A53F-928610FBCD53Q38834785-1FE3E83C-401B-40D5-A579-E518851E6A22Q38924056-BA6883C5-76CE-408B-8D7E-FAF8856DFADDQ41233246-0EFC4ED9-11D8-40A7-B002-7F45DC0A7DCFQ41239989-E7816D6C-8666-4468-8D34-B2F511B95327Q42041489-B8551C38-5430-4C85-ACBB-6A8FEA50DE3AQ42249160-8DC6B1ED-7CAC-4756-AE46-DA3DFF66D370Q43238527-ED46DB35-01AC-4A83-BD26-15EBF05D7807Q46781768-9A7A7204-8109-4F6E-92B4-BBBF09AB1927Q47103256-F1402C72-E6F1-4E0A-9F32-F7415D73D23DQ47129762-CC64582B-645B-47E3-BB72-65B5811C2E4AQ47161019-3696B997-A811-4308-98B7-5E0F0E49A7A4Q50070105-F3C346F7-154C-4285-BCE1-4EC879A4CC7CQ50318305-2BE23650-90E3-451C-8530-FB0EA18AF750Q51123259-63E480C3-8529-4A59-8F25-5E8C53FC2282Q51176917-637E3A4F-98D1-4475-9C55-D039BCE27A8CQ52579567-1CB9F0B9-5AA6-40A8-AFCF-468F78490D01Q55022368-9DD88073-78F9-4337-8FE7-1F52EF73EDD8Q55181844-C9533F84-109F-482F-8ACD-2AE867DC7867Q55340117-E3DFA65E-4EFE-43B5-92C8-FB7A63F8FFC7Q58730696-7E828168-36F3-4A93-B109-1F2387D283C1
P2860
Trailing TRAIL Resistance: Novel Targets for TRAIL Sensitization in Cancer Cells
description
2015 nî lūn-bûn
@nan
2015 թուականին հրատարակուած գիտական յօդուած
@hyw
2015 թվականին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Trailing TRAIL Resistance: Novel Targets for TRAIL Sensitization in Cancer Cells
@ast
Trailing TRAIL Resistance: Novel Targets for TRAIL Sensitization in Cancer Cells
@en
Trailing TRAIL Resistance: Novel Targets for TRAIL Sensitization in Cancer Cells
@nl
type
label
Trailing TRAIL Resistance: Novel Targets for TRAIL Sensitization in Cancer Cells
@ast
Trailing TRAIL Resistance: Novel Targets for TRAIL Sensitization in Cancer Cells
@en
Trailing TRAIL Resistance: Novel Targets for TRAIL Sensitization in Cancer Cells
@nl
prefLabel
Trailing TRAIL Resistance: Novel Targets for TRAIL Sensitization in Cancer Cells
@ast
Trailing TRAIL Resistance: Novel Targets for TRAIL Sensitization in Cancer Cells
@en
Trailing TRAIL Resistance: Novel Targets for TRAIL Sensitization in Cancer Cells
@nl
P2860
P3181
P356
P1476
Trailing TRAIL Resistance: Novel Targets for TRAIL Sensitization in Cancer Cells
@en
P2093
Durga Prasad Mishra
Rachana Trivedi
P2860
P3181
P356
10.3389/FONC.2015.00069
P407
P577
2015-01-01T00:00:00Z